VYNE Therapeutics Inc.
General ticker "VYNE" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $64.0M (TTM average)
VYNE Therapeutics Inc. does not follow the US Stock Market performance with the rate: -21.1%.
Estimated limits based on current volatility of 3.2%: low 0.36$, high 0.38$
Factors to consider:
- Total employees count: 13 (+30.0%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Product development risks, Strategic risks and growth management, Cybersecurity threats, Labor/talent shortage/retention, Regulatory and compliance
- Current price 73.6% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.42$, 4.35$]
- 2025-12-31 to 2026-12-31 estimated range: [0.85$, 2.77$]
Financial Metrics affecting the VYNE estimates:
- Positive: with PPE of -3.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -27.84 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 77.85 > 63.39
Short-term VYNE quotes
Long-term VYNE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.48MM | $0.42MM | $0.50MM |
| Operating Expenses | $34.77MM | $29.68MM | $44.14MM |
| Operating Income | $-34.30MM | $-29.26MM | $-43.64MM |
| Non-Operating Income | $0.36MM | $1.39MM | $3.83MM |
| R&D Expense | $18.39MM | $16.31MM | $30.95MM |
| Income(Loss) | $-33.93MM | $-27.87MM | $-39.80MM |
| Taxes | $0.01MM | $0.00MM | $0.00MM |
| Other Income(Loss) | $10.73MM | $-0.58MM | $-0.03MM |
| Profit(Loss)* | $-33.95MM | $-29.03MM | $-39.86MM |
| Stockholders Equity | $31.20MM | $88.73MM | $52.09MM |
| Assets | $40.76MM | $97.69MM | $66.91MM |
| Operating Cash Flow | $-29.20MM | $-25.34MM | $-33.97MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.12MM |
| Investing Cash Flow | $15.67MM | $-57.35MM | $23.36MM |
| Financing Cash Flow | $1.65MM | $82.39MM | $-0.14MM |
| Earnings Per Share** | $-10.65 | $-2.83 | $-0.94 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.